[Cited FineTest ELISA Kit] Current Research on Post-Stroke Pneumonia

FineTest ELISA kit contributes to the research on post-stroke pneumonia. The immunoassay is designed to measure DCD concentration in BM-MSC, migrasomes, or plasma.

Publication Details
Article Title: Bone Marrow Mesenchymal Stem Cell-Derived Dermcidin-Containing Migrasomes enhance LC3-Associated Phagocytosis of Pulmonary Macrophages and Protect against Post-Stroke Pneumonia
Journal Title: Advanced Science
DOI: 10.1002/advs.202206432
IF: 15.1
PMID: 37246283

Abstract: Pneumonia is one of the leading causes of death in patients with acute ischemic stroke (AIS). Antibiotics fail to improve prognosis of patients with post-stroke pneumonia, albeit suppressing infection, due to adverse impacts on the immune system. The current study reports that bone marrow mesenchymal stem cells (BM-MSC) downregulate bacterial load in the lungs of stroke mice models. RNA-sequencing of the lung from BM-MSC-treated stroke models indicates that BM-MSC modulates pulmonary macrophage activities after cerebral ischemia. Mechanistically, BM-MSC promotes the bacterial phagocytosis of pulmonary macrophages through releasing migrasomes, which are migration-dependent extracellular vesicles. With liquid chromatography-tandem mass spectrometry (LC-MS/MS), the result shows that BM-MSC are found to load the antibacterial peptide dermcidin (DCD) in migrasomes upon bacterial stimulation. Besides the antibiotic effect, DCD enhances LC3-associated phagocytosis (LAP) of macrophages, facilitating their bacterial clearance. The data demonstrate that BM-MSC is a promising therapeutic candidate against post-stroke pneumonia, with dual functions of anti-infection and immunol modulation, which is more than a match for antibiotics treatment.

Keywords: bone marrow mesenchymal stem cell, macrophage, migrasome, post-stroke pneumonia

Immunoassay

Validated Image

Figure Source: Adv Sci (Weinh). 2023 Aug;10(22):e2206432. doi: 10.1002/advs.202206432.